The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality ...
Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...
Millions of South Africa are suffering with symptoms generally known as Long Covid. This growing crisis is shattering lives, ...
News Medical on MSN2d
Inhaled antibody therapy shows promise for COVID-19 treatmentThe inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.
Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...
People with immune system health problems continue to take precautions against COVID-19 five years into the pandemic.
Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback